 Toby Trujillo
Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 22 | 2023 | 615 | 3.500 |
Why?
| | Venous Thromboembolism | 17 | 2025 | 271 | 2.980 |
Why?
| | Factor Xa Inhibitors | 7 | 2025 | 169 | 1.700 |
Why?
| | Acute Coronary Syndrome | 4 | 2020 | 267 | 1.390 |
Why?
| | Hemorrhage | 10 | 2022 | 643 | 1.180 |
Why?
| | Thrombosis | 6 | 2023 | 323 | 1.070 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2023 | 439 | 1.000 |
Why?
| | Students, Pharmacy | 2 | 2016 | 96 | 0.910 |
Why?
| | Pharmacy Residencies | 2 | 2014 | 11 | 0.900 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2023 | 16 | 0.870 |
Why?
| | Education, Pharmacy | 2 | 2016 | 119 | 0.860 |
Why?
| | Blood Coagulation | 4 | 2021 | 226 | 0.850 |
Why?
| | Geriatrics | 1 | 2023 | 80 | 0.810 |
Why?
| | Atrial Fibrillation | 4 | 2022 | 374 | 0.790 |
Why?
| | Percutaneous Coronary Intervention | 2 | 2020 | 466 | 0.750 |
Why?
| | Warfarin | 3 | 2022 | 142 | 0.730 |
Why?
| | Piperazines | 4 | 2019 | 332 | 0.710 |
Why?
| | Blood Coagulation Factors | 1 | 2020 | 47 | 0.680 |
Why?
| | Factor Xa | 4 | 2021 | 32 | 0.630 |
Why?
| | Vitamin K | 1 | 2019 | 40 | 0.620 |
Why?
| | Rivaroxaban | 8 | 2025 | 252 | 0.620 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 162 | 0.610 |
Why?
| | Angina Pectoris | 2 | 2007 | 67 | 0.570 |
Why?
| | Acetanilides | 2 | 2007 | 11 | 0.560 |
Why?
| | Dalteparin | 2 | 2014 | 10 | 0.540 |
Why?
| | Fibrinolytic Agents | 2 | 2014 | 248 | 0.510 |
Why?
| | Practice Guidelines as Topic | 6 | 2020 | 1482 | 0.490 |
Why?
| | Thrombocytopenia | 2 | 2014 | 184 | 0.470 |
Why?
| | Antithrombins | 4 | 2020 | 54 | 0.470 |
Why?
| | Morpholines | 2 | 2014 | 122 | 0.460 |
Why?
| | Thiophenes | 2 | 2014 | 118 | 0.460 |
Why?
| | Patient-Centered Care | 2 | 2016 | 493 | 0.450 |
Why?
| | Recombinant Proteins | 6 | 2021 | 1286 | 0.440 |
Why?
| | Cardiovascular Diseases | 5 | 2023 | 1994 | 0.440 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 809 | 0.430 |
Why?
| | Humans | 54 | 2025 | 128019 | 0.390 |
Why?
| | Administration, Oral | 7 | 2022 | 766 | 0.380 |
Why?
| | Arginine | 5 | 2020 | 259 | 0.340 |
Why?
| | Pyridones | 5 | 2021 | 158 | 0.330 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2010 | 139 | 0.320 |
Why?
| | Fibrinolysis | 1 | 2010 | 133 | 0.310 |
Why?
| | Myocardial Infarction | 2 | 2020 | 1013 | 0.310 |
Why?
| | Electric Countershock | 2 | 2019 | 105 | 0.290 |
Why?
| | Pyrazoles | 5 | 2021 | 401 | 0.290 |
Why?
| | Arrhythmias, Cardiac | 1 | 2010 | 314 | 0.280 |
Why?
| | Heparin | 4 | 2016 | 246 | 0.270 |
Why?
| | Aged | 14 | 2025 | 21892 | 0.270 |
Why?
| | Angina, Stable | 1 | 2006 | 17 | 0.260 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2006 | 21 | 0.260 |
Why?
| | Thrombin | 2 | 2020 | 143 | 0.260 |
Why?
| | Drug Interactions | 5 | 2016 | 361 | 0.250 |
Why?
| | Pharmacists | 3 | 2014 | 246 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2020 | 1356 | 0.240 |
Why?
| | Sucrose | 1 | 2005 | 94 | 0.240 |
Why?
| | Thromboembolism | 2 | 2016 | 101 | 0.230 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2005 | 130 | 0.230 |
Why?
| | Diet | 1 | 2012 | 1198 | 0.220 |
Why?
| | Dabigatran | 4 | 2016 | 21 | 0.220 |
Why?
| | Pipecolic Acids | 3 | 2020 | 25 | 0.220 |
Why?
| | Hirudins | 3 | 2020 | 52 | 0.210 |
Why?
| | Inappropriate Prescribing | 1 | 2023 | 52 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 754 | 0.200 |
Why?
| | Aged, 80 and over | 5 | 2025 | 7029 | 0.200 |
Why?
| | Middle Aged | 11 | 2025 | 30812 | 0.190 |
Why?
| | Antiphospholipid Syndrome | 1 | 2021 | 32 | 0.180 |
Why?
| | Coronary Artery Disease | 1 | 2007 | 675 | 0.180 |
Why?
| | Prothrombin | 1 | 2021 | 18 | 0.180 |
Why?
| | Aspirin | 2 | 2023 | 377 | 0.180 |
Why?
| | Male | 17 | 2025 | 62757 | 0.180 |
Why?
| | Pharmaceutical Services | 2 | 2013 | 81 | 0.180 |
Why?
| | Hospitalization | 3 | 2025 | 2057 | 0.170 |
Why?
| | Stroke | 2 | 2022 | 1063 | 0.170 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 109 | 0.170 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 64 | 0.170 |
Why?
| | Female | 17 | 2025 | 68016 | 0.170 |
Why?
| | Intracranial Hemorrhages | 1 | 2020 | 79 | 0.170 |
Why?
| | Neoplasms | 1 | 2014 | 2460 | 0.160 |
Why?
| | Peptide Fragments | 3 | 2020 | 688 | 0.160 |
Why?
| | Communication | 2 | 2016 | 838 | 0.160 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2020 | 120 | 0.160 |
Why?
| | Secondary Prevention | 1 | 2020 | 217 | 0.160 |
Why?
| | Chi-Square Distribution | 1 | 2020 | 511 | 0.160 |
Why?
| | Adult | 10 | 2025 | 35176 | 0.160 |
Why?
| | Blood Coagulation Tests | 2 | 2016 | 53 | 0.150 |
Why?
| | Electrodiagnosis | 1 | 2018 | 15 | 0.150 |
Why?
| | Obesity, Morbid | 1 | 2022 | 239 | 0.150 |
Why?
| | Goals | 1 | 2020 | 160 | 0.150 |
Why?
| | Retrospective Studies | 8 | 2022 | 14404 | 0.150 |
Why?
| | Critical Illness | 1 | 2023 | 755 | 0.140 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1012 | 0.140 |
Why?
| | Acute Kidney Injury | 1 | 2005 | 777 | 0.140 |
Why?
| | Ranolazine | 2 | 2007 | 25 | 0.140 |
Why?
| | Chronic Disease | 3 | 2007 | 1690 | 0.140 |
Why?
| | Electrocardiography | 2 | 2010 | 607 | 0.140 |
Why?
| | Partial Thromboplastin Time | 2 | 2014 | 51 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 997 | 0.130 |
Why?
| | Healthcare Disparities | 2 | 2014 | 579 | 0.130 |
Why?
| | Coronary Disease | 1 | 1998 | 384 | 0.130 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 536 | 0.120 |
Why?
| | Catheter Ablation | 1 | 2019 | 333 | 0.120 |
Why?
| | United States | 5 | 2020 | 13785 | 0.120 |
Why?
| | Medicare | 1 | 2020 | 715 | 0.110 |
Why?
| | Educational Measurement | 1 | 2016 | 257 | 0.110 |
Why?
| | Venous Thrombosis | 1 | 2016 | 161 | 0.110 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 90 | 0.110 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 86 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2016 | 202 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1943 | 0.110 |
Why?
| | Treatment Outcome | 5 | 2020 | 10110 | 0.100 |
Why?
| | Hip Joint | 1 | 2014 | 157 | 0.100 |
Why?
| | Perioperative Care | 2 | 2014 | 149 | 0.100 |
Why?
| | Emergency Treatment | 1 | 2013 | 113 | 0.100 |
Why?
| | History, 21st Century | 1 | 2013 | 177 | 0.100 |
Why?
| | Glycemic Index | 1 | 2012 | 24 | 0.100 |
Why?
| | Edible Grain | 1 | 2012 | 48 | 0.100 |
Why?
| | Surgical Procedures, Operative | 1 | 2014 | 243 | 0.100 |
Why?
| | Blood Transfusion | 1 | 2014 | 291 | 0.100 |
Why?
| | History, 20th Century | 1 | 2013 | 285 | 0.100 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2012 | 32 | 0.090 |
Why?
| | Diet, Sodium-Restricted | 1 | 2012 | 33 | 0.090 |
Why?
| | Dietary Fiber | 1 | 2012 | 49 | 0.090 |
Why?
| | Diet, Fat-Restricted | 1 | 2012 | 80 | 0.090 |
Why?
| | Diet, Mediterranean | 1 | 2012 | 29 | 0.090 |
Why?
| | Clinical Competence | 2 | 2016 | 1007 | 0.090 |
Why?
| | Risk Factors | 2 | 2020 | 9696 | 0.090 |
Why?
| | Forecasting | 1 | 2013 | 355 | 0.090 |
Why?
| | Fruit | 1 | 2012 | 131 | 0.090 |
Why?
| | Empirical Research | 1 | 2011 | 21 | 0.090 |
Why?
| | Vegetables | 1 | 2012 | 147 | 0.090 |
Why?
| | Dietary Proteins | 1 | 2012 | 128 | 0.090 |
Why?
| | Research | 1 | 2014 | 408 | 0.090 |
Why?
| | Nomograms | 1 | 2011 | 47 | 0.090 |
Why?
| | Curriculum | 1 | 2016 | 909 | 0.080 |
Why?
| | Self Care | 1 | 2013 | 368 | 0.080 |
Why?
| | Insurance Coverage | 1 | 2011 | 219 | 0.080 |
Why?
| | Polysaccharides | 1 | 2010 | 85 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 6479 | 0.080 |
Why?
| | Life Style | 1 | 2012 | 459 | 0.080 |
Why?
| | Pharmacy Service, Hospital | 1 | 2010 | 90 | 0.080 |
Why?
| | Complementary Therapies | 1 | 2010 | 85 | 0.080 |
Why?
| | Patient Care Team | 1 | 2014 | 597 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1272 | 0.070 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2010 | 135 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2010 | 242 | 0.070 |
Why?
| | Job Satisfaction | 1 | 2010 | 201 | 0.070 |
Why?
| | Patient Acceptance of Health Care | 1 | 2014 | 756 | 0.070 |
Why?
| | Thrombin Time | 2 | 2020 | 11 | 0.070 |
Why?
| | Myocardial Revascularization | 1 | 2007 | 70 | 0.070 |
Why?
| | Sulfonamides | 3 | 2020 | 494 | 0.070 |
Why?
| | Bariatric Surgery | 1 | 2010 | 192 | 0.070 |
Why?
| | Delayed-Action Preparations | 1 | 2007 | 170 | 0.070 |
Why?
| | Intensive Care Units | 2 | 2023 | 734 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2020 | 478 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 5353 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 370 | 0.060 |
Why?
| | Prostaglandins | 1 | 2006 | 84 | 0.060 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2006 | 65 | 0.060 |
Why?
| | Long QT Syndrome | 1 | 2006 | 67 | 0.060 |
Why?
| | Excipients | 1 | 2005 | 51 | 0.060 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2005 | 103 | 0.060 |
Why?
| | beta-Alanine | 2 | 2014 | 16 | 0.060 |
Why?
| | Animals | 5 | 2019 | 34487 | 0.060 |
Why?
| | Obesity | 2 | 2023 | 2859 | 0.050 |
Why?
| | Acute Disease | 2 | 2014 | 961 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 332 | 0.050 |
Why?
| | Thromboxane B2 | 1 | 2023 | 26 | 0.050 |
Why?
| | Benzimidazoles | 2 | 2014 | 158 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2023 | 199 | 0.050 |
Why?
| | Prospective Studies | 2 | 2025 | 7035 | 0.050 |
Why?
| | Thinness | 1 | 2022 | 89 | 0.050 |
Why?
| | Pharmacokinetics | 1 | 2000 | 24 | 0.040 |
Why?
| | Thrombelastography | 1 | 2021 | 147 | 0.040 |
Why?
| | Professional Role | 2 | 2013 | 156 | 0.040 |
Why?
| | Disease Progression | 1 | 2007 | 2598 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 206 | 0.040 |
Why?
| | Allied Health Personnel | 1 | 2020 | 40 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 390 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 550 | 0.040 |
Why?
| | Hemostasis | 1 | 2019 | 71 | 0.040 |
Why?
| | Syndrome | 1 | 1998 | 332 | 0.040 |
Why?
| | Young Adult | 2 | 2025 | 12281 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5378 | 0.040 |
Why?
| | Body Weight | 1 | 2021 | 930 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 631 | 0.030 |
Why?
| | Risk Assessment | 1 | 2006 | 3223 | 0.030 |
Why?
| | Heart Failure | 1 | 2010 | 2141 | 0.030 |
Why?
| | Quality of Life | 1 | 2007 | 2672 | 0.030 |
Why?
| | Calibration | 1 | 2016 | 135 | 0.030 |
Why?
| | Thiazoles | 1 | 2016 | 115 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 850 | 0.030 |
Why?
| | Body Mass Index | 1 | 2023 | 2260 | 0.030 |
Why?
| | Thromboplastin | 1 | 2014 | 69 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2014 | 253 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2014 | 190 | 0.030 |
Why?
| | Pyridines | 1 | 2016 | 474 | 0.020 |
Why?
| | Incidence | 1 | 2019 | 2614 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2011 | 127 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 275 | 0.020 |
Why?
| | Pharmacy Administration | 1 | 2010 | 1 | 0.020 |
Why?
| | Societies, Pharmaceutical | 1 | 2010 | 21 | 0.020 |
Why?
| | Health Care Costs | 1 | 2013 | 366 | 0.020 |
Why?
| | Career Mobility | 1 | 2010 | 68 | 0.020 |
Why?
| | Micronutrients | 1 | 2010 | 88 | 0.020 |
Why?
| | Awards and Prizes | 1 | 2010 | 60 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 709 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 523 | 0.020 |
Why?
| | Food | 1 | 2010 | 154 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 583 | 0.020 |
Why?
| | Reward | 1 | 2010 | 237 | 0.020 |
Why?
| | Length of Stay | 1 | 2011 | 1114 | 0.020 |
Why?
| | Patient Readmission | 1 | 2011 | 663 | 0.020 |
Why?
| | Adolescent | 1 | 2025 | 20158 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2010 | 531 | 0.020 |
Why?
| | Internet | 1 | 2010 | 613 | 0.020 |
Why?
| | Motivation | 1 | 2010 | 544 | 0.010 |
Why?
|
|
Trujillo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|